Live and live-attenuated bacterial vectors have been extensively studied for their applications in gene therapy, oncolytic bacterial therapy, vaccines, and more. Various bacterial strains, including Bifidobacteria, Salmonella, Escherichia coli, and Listeria monocytogenes, may be naturally sourced, engineered, or genetically modified to enhance their therapeutic potential. In 2016, the FDA defined these bacterial vectors for drug delivery systems as microbial vectors used for gene therapy (MVGT) to express human tumor antigens, cytokines, growth factors, enzymes, therapeutic proteins, or nucleotides. To help global clients translate their research into clinical applications more efficiently, Porton Advanced leverages its extensive experience to provide integrated CDMO services ranging from microbial banking to aseptic filling and finishing of injectables.
The scientists at Porton Advanced possess extensive knowledge and hands-on experience in handling naturally screened, engineered, and genetically modified bacterial strains, including Salmonella, Escherichia coli, Listeria monocytogenes, and more. Our state-of-the-art facility is fully equipped with bioreactors for aerobic and anaerobic fermentation, ultrafiltration liquid exchange systems, and sterility assurance systems.
We offer integrated CMC services for bacterial vectors:
Porton Advanced's capability spans from aerobic to strictly anaerobic bacterial strains.
| Strain Type | Source | Examples |
|---|---|---|
| Wild-type strain domestication | Strains from customer or compliant suppliers | Lactobacillus acidophilus Lactobacillus plantarum Enterococcus faecium |
| Wild-type strain domestication | Staphylococcus aureus Salmonella |
|
| Strains engineered with plasmids | Attenuated Listeria monocytogenes (including GOI plasmid) | |
| Genetically modified strains | Attenuated Salmonella (Metabolic gene mutation and functional gene expression) |
Here is an example testing list for final injectables of oncolytic bacteria therapy:
Please consult with our experts for a complete list of tests available.
Porton Advanced can deliver a bacterial vector-related IND CMC project, from clone screening to GMP production and QC release, within 6 to 7 months.
